XCells Biotechnologies ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, and Rosebud ...
StemEdit encompasses REPROCELL's proprietary clinical gene-editing technology and its new gene-edited iPSC lines that are ready for immediate use. These offerings combine REPROCELL's StemRNA™ Clinical ...
Zacks Investment Research on MSN
Century Therapeutics (IPSC) upgraded to strong buy: Here's what you should know
Century Therapeutics, Inc. (IPSC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
Explore scalable strategies for iPSC-derived islet differentiation using GMP-grade activin A and KGF to advance diabetes ...
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Century ...
Designation underscores the potential of this chemically induced, off-the-shelf cell therapy to address a high unmet need in ...
Alongside the complete kit, TheWell Bioscience has released the RocketCell (TM) iPSC Xeno-Free Growth Medium. Available as a standalone product, this xeno-free medium is designed for researchers who ...
) has been revised to $4.08 / share. This is a decrease of 20.00% from the prior estimate of $5.10 dated November 14, 2025. The price target is an average of many targets provided by analysts. The ...
Organoids are an important component of translational research, particularly for evaluating drug toxicity and tissue-specific responses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results